FDA accuses firm of selling unapproved drugs
This article was originally published in The Tan Sheet
Executive SummaryUnder a consent decree with FDA, Risingsun Health and the Center for Complimentary and Alternative Health in Livingston, Mont., agree to hire an independent expert for pre-market review of product claims and to certify the claims are compliant. The decree, which also prohibits the firms from selling unapproved new drugs, was filed in the U.S. District Court for the District of Montana and resolves charges the firm sold ineffective products. Prior to signing the decree, Risingsun made and distributed unapproved new drugs, including Black Salve, Cancema and Can-Support, purported to treat cancer, asthma, anemia and epilepsy, FDA said Oct. 13
You may also be interested in...
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.
Quanta Dialysis is linking up with B. Braun Avitum UK to support patients with Quanta’s personal hemodialysis device in the home. See what Quanta CEO John Milad said about it here.
Cosmetics Europe’s Director-General John Chave discusses next steps in the European Union’s proposed drive to ban manufactured microplastic in all cosmetic products. Industry continues to fight for something more proportionate, but it’s up against powerful forces in today’s European theater.